CHMP Recommends Approval Of Janssen's Rybrevant (Amivantamab) And Lazcluze (Lazertinib) Combo For First-Line Treatment Of EGFR-Mutated Advanced NSCLC, Potentially Establishing New Standard Of Care Pending European Commission Approval
CHMP Recommends Approval Of Janssen's Rybrevant (Amivantamab) And Lazcluze (Lazertinib) Combo For First-Line Treatment Of EGFR-Mutated Advanced NSCLC, Potentially Establishing New Standard Of Care Pending European Commission Approval
CHMP推薦批准雅培的Rybrevant（阿米萬單抗）和Lazcluze（拉澤替尼）聯合用於EGFR突變的晚期非小細胞肺癌的一線治療，可能建立新的護理標準，待歐洲委員會批准
CHMP Recommends Approval Of Janssen's Rybrevant (Amivantamab) And Lazcluze (Lazertinib) Combo For First-Line Treatment Of EGFR-Mutated Advanced NSCLC, Potentially Establishing New Standard Of Care Pending European Commission Approval
CHMP推薦批准雅培的Rybrevant（阿米萬單抗）和Lazcluze（拉澤替尼）聯合用於EGFR突變的晚期非小細胞肺癌的一線治療，可能建立新的護理標準，待歐洲委員會批准
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間